An investigation on behalf of investors in C R Bard Inc (NYSE:BCR) shares over potential wrongdoing at C R Bard Inc was announced and NYSE:BCR stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 02/08/2016 -- An investigation for shareholders in C R Bard Inc (NYSE:BCR) was announced over potential breaches of fiduciary duties by certain directors at C R Bard Inc. More specifically, the investigation concerns whether C.R. Bard potentially knew about fatal flaws associated with the G2 series filters they manufactured.
Investors who purchased shares of C R Bard Inc (NYSE:BCR) have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain C R Bard officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
According to the investigation the modified version of the blood-clot filter was meant to replace the original Recovery Filter, but was similarly mired by device flaws. According to the investigation the Recovery filter was found to have higher rates of relative risk of filter facture, movement, and death according to a confidential study commissioned by C.R. Bard, that the G2 filter had similar problems and now, hundreds of complications and at least twelve deaths have been linked to the device, and that instead of recalling the G2 filter, C.R. Bard kept it on the market for five subsequent years.
On February 4, 2016, NYSE:BCR shares closed at $187.13 per share.
Those who purchased shares of C R Bard Inc (NYSE:BCR), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego